Skip to main content
Erschienen in: Cancer Causes & Control 8/2010

01.08.2010 | Original paper

Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain

verfasst von: Laia Domingo, Maria Sala, Sònia Servitja, Josep Maria Corominas, Francisco Ferrer, Juan Martínez, Francesc Macià, Maria Jesús Quintana, Joan Albanell, Xavier Castells

Erschienen in: Cancer Causes & Control | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

To analyze phenotypic classification and other risk factors for interval breast cancer, focusing on true interval and false negative cancers.

Methods

A nested case–control study was performed among 115 cancers detected between two screening mammograms (interval cancers) and 115 screen-detected cancers diagnosed between 1995 and 2008 in a population-based breast cancer screening program in Barcelona (Spain). Bivariate and multivariate analyses were performed to compare patient and tumor molecular characteristics among all interval cancers, true intervals and false negatives, and screen-detected cancers.

Results

A total of 42.5% of interval cancers were true interval tumors and 16.2% were false negatives. High breast density and triple negative phenotype were more frequent in true interval cancers than in screen-detected cancers (57.6 and 34.1%, respectively for breast density, p = 0.023; 28.1 and 7.5%, respectively for triple negative phenotype, p = 0.028), while no statistically significant differences were observed between false negatives and screen-detected cancers. The main adjusted factors associated with true interval cancers compared with screen-detected cancers were high breast density and triple negative phenotype (OR = 3.1, 95% CI, 1.03–9.24 and OR = 8.9, 95% CI, 2.03–38.62, respectively).

Conclusion

A more aggressive molecular phenotype and high breast density were identified in breast tumors that truly arise in the interval between screenings.
Literatur
1.
Zurück zum Zitat Rakha EA, El Sayed ME, Reis-Filho JS, Ellis IO (2008) Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 52:67–81PubMed Rakha EA, El Sayed ME, Reis-Filho JS, Ellis IO (2008) Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology 52:67–81PubMed
2.
Zurück zum Zitat Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463–1479CrossRefPubMed Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC (2009) Early breast cancer. Lancet 373:1463–1479CrossRefPubMed
3.
Zurück zum Zitat Tornberg S, Codd M, Rodrigues V, Segnan N, Ponti A (2005) Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centers. J Med Screen 12:43–49CrossRefPubMed Tornberg S, Codd M, Rodrigues V, Segnan N, Ponti A (2005) Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centers. J Med Screen 12:43–49CrossRefPubMed
4.
Zurück zum Zitat Perry N, Broeders M, de Wolf C, Törnberg C, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg Perry N, Broeders M, de Wolf C, Törnberg C, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
5.
Zurück zum Zitat Vitak B, Olsen KE, Manson JC, Arnesson LG, Stal O (1999) Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. Eur Radiol 9:460–469CrossRefPubMed Vitak B, Olsen KE, Manson JC, Arnesson LG, Stal O (1999) Tumour characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. Eur Radiol 9:460–469CrossRefPubMed
6.
Zurück zum Zitat Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220–1228CrossRefPubMed Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996) Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220–1228CrossRefPubMed
7.
Zurück zum Zitat Cowan WK, Angus B, Gray JC, Lunt LG, al Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53:140–146CrossRefPubMed Cowan WK, Angus B, Gray JC, Lunt LG, al Tamimi SR (2000) A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53:140–146CrossRefPubMed
8.
Zurück zum Zitat Porter PL, El Bastawissi AY, Mandelson MT (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028CrossRefPubMed Porter PL, El Bastawissi AY, Mandelson MT (1999) Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020–2028CrossRefPubMed
9.
Zurück zum Zitat Burrell HC, Sibbering DM, Wilson AR (1996) Screening interval breast cancers: mammographic features and prognosis factors. Radiology 199:811–817PubMed Burrell HC, Sibbering DM, Wilson AR (1996) Screening interval breast cancers: mammographic features and prognosis factors. Radiology 199:811–817PubMed
10.
Zurück zum Zitat Collett K, Stefansson IM, Eide J (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108–1112CrossRefPubMed Collett K, Stefansson IM, Eide J (2005) A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108–1112CrossRefPubMed
11.
Zurück zum Zitat Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682–2688PubMed Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (1999) Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682–2688PubMed
12.
Zurück zum Zitat Gilliland FD, Joste N, Stauber PM (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743–749CrossRefPubMed Gilliland FD, Joste N, Stauber PM (2000) Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743–749CrossRefPubMed
13.
Zurück zum Zitat Palka I, Kelemen G, Ormandi K (2008) Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 14:161–167CrossRefPubMed Palka I, Kelemen G, Ormandi K (2008) Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 14:161–167CrossRefPubMed
14.
Zurück zum Zitat Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M (2003) Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 23:4213–4218PubMed Anttinen J, Kuopio T, Nykanen M, Torkkeli H, Saari U, Juhola M (2003) Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers. Anticancer Res 23:4213–4218PubMed
15.
Zurück zum Zitat Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799–2805CrossRefPubMed Irvin WJ Jr, Carey LA (2008) What is triple-negative breast cancer? Eur J Cancer 44:2799–2805CrossRefPubMed
16.
Zurück zum Zitat Bare M, Sentis M, Galceran J (2008) Interval breast cancers in a community screening programme: frequency, radiological classification and prognostic factors. Eur J Cancer Prev 17:414–421CrossRefPubMed Bare M, Sentis M, Galceran J (2008) Interval breast cancers in a community screening programme: frequency, radiological classification and prognostic factors. Eur J Cancer Prev 17:414–421CrossRefPubMed
17.
Zurück zum Zitat Hofvind S, Geller B, Skaane P (2008) Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 49:975–981CrossRefPubMed Hofvind S, Geller B, Skaane P (2008) Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 49:975–981CrossRefPubMed
18.
Zurück zum Zitat Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118:3112–3117CrossRefPubMed Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118:3112–3117CrossRefPubMed
19.
Zurück zum Zitat Mandelson MT, Oestreicher N, Porter PL (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92:1081–1087CrossRefPubMed Mandelson MT, Oestreicher N, Porter PL (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92:1081–1087CrossRefPubMed
20.
Zurück zum Zitat Ciatto S, Visioli C, Paci E, Zappa M (2004) Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer 90:393–396CrossRefPubMed Ciatto S, Visioli C, Paci E, Zappa M (2004) Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer 90:393–396CrossRefPubMed
21.
Zurück zum Zitat Porter GJ, Evans AJ, Cornford EJ (2007) Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 188:676–683CrossRefPubMed Porter GJ, Evans AJ, Cornford EJ (2007) Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 188:676–683CrossRefPubMed
22.
Zurück zum Zitat Boyd NF, Rommens JM, Vogt K (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed Boyd NF, Rommens JM, Vogt K (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6:798–808CrossRefPubMed
23.
Zurück zum Zitat Harvey JA, Bovbjerg VE (2004) Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 230:29–41CrossRefPubMed Harvey JA, Bovbjerg VE (2004) Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 230:29–41CrossRefPubMed
24.
Zurück zum Zitat Li T, Sun L, Miller N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14:343–349CrossRefPubMed Li T, Sun L, Miller N (2005) The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 14:343–349CrossRefPubMed
25.
Zurück zum Zitat Guo YP, Martin LJ, Hanna W (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed Guo YP, Martin LJ, Hanna W (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10:243–248PubMed
26.
Zurück zum Zitat Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379–6391CrossRefPubMed Pike MC, Pearce CL, Wu AH (2004) Prevention of cancers of the breast, endometrium and ovary. Oncogene 23:6379–6391CrossRefPubMed
27.
Zurück zum Zitat Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K (2003) Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 95:556–558CrossRefPubMed Ziv E, Shepherd J, Smith-Bindman R, Kerlikowske K (2003) Mammographic breast density and family history of breast cancer. J Natl Cancer Inst 95:556–558CrossRefPubMed
28.
Zurück zum Zitat Kopans DB (2008) Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 246:348–353CrossRefPubMed Kopans DB (2008) Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 246:348–353CrossRefPubMed
29.
Zurück zum Zitat Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA (2006) Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 13:1143–1149CrossRefPubMed Nicholson BT, LoRusso AP, Smolkin M, Bovbjerg VE, Petroni GR, Harvey JA (2006) Accuracy of assigned BI-RADS breast density category definitions. Acad Radiol 13:1143–1149CrossRefPubMed
30.
Zurück zum Zitat Kavanagh AM, Cawson J, Byrnes GB (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14:1060–1064CrossRefPubMed Kavanagh AM, Cawson J, Byrnes GB (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14:1060–1064CrossRefPubMed
31.
Zurück zum Zitat Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8:29–34CrossRefPubMed Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 8:29–34CrossRefPubMed
32.
Zurück zum Zitat Porter GJ, Evans AJ, Burrell HC, Lee AH, Ellis IO, Chakrabarti J (2006) Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 13:115–122CrossRefPubMed Porter GJ, Evans AJ, Burrell HC, Lee AH, Ellis IO, Chakrabarti J (2006) Interval breast cancers: prognostic features and survival by subtype and time since screening. J Med Screen 13:115–122CrossRefPubMed
33.
Zurück zum Zitat Tan DS, Marchio C, Jones RL (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44CrossRefPubMed Tan DS, Marchio C, Jones RL (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27–44CrossRefPubMed
34.
Zurück zum Zitat Dolle JM, Daling JR, White E (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18:1157–1166CrossRefPubMed Dolle JM, Daling JR, White E (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 18:1157–1166CrossRefPubMed
35.
Zurück zum Zitat Haffty BG, Yang Q, Reiss M (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed Haffty BG, Yang Q, Reiss M (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMed
36.
Zurück zum Zitat Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G (2009) Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18:479–485CrossRefPubMed Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G (2009) Is there a difference in the association between percent mammographic density and subtypes of breast cancer? Luminal A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev 18:479–485CrossRefPubMed
37.
Zurück zum Zitat Ciatto S, Catarzi S, Lamberini MP (2007) Interval breast cancers in screening: the effect of mammography review method on classification. Breast 16:646–652CrossRefPubMed Ciatto S, Catarzi S, Lamberini MP (2007) Interval breast cancers in screening: the effect of mammography review method on classification. Breast 16:646–652CrossRefPubMed
Metadaten
Titel
Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain
verfasst von
Laia Domingo
Maria Sala
Sònia Servitja
Josep Maria Corominas
Francisco Ferrer
Juan Martínez
Francesc Macià
Maria Jesús Quintana
Joan Albanell
Xavier Castells
Publikationsdatum
01.08.2010
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 8/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9541-6

Weitere Artikel der Ausgabe 8/2010

Cancer Causes & Control 8/2010 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.